메뉴 건너뛰기




Volumn 63, Issue 11, 2014, Pages 1695-1699

Use of azathioprine in IBD: Modern aspects of an old drug

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; MERCAPTOPURINE; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

EID: 84907796504     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306711     Document Type: Article
Times cited : (37)

References (66)
  • 1
    • 67650416300 scopus 로고    scopus 로고
    • Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
    • Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;1:CD000067.
    • (2009) Cochrane Database Syst Rev , vol.1 , pp. CD000067
    • Prefontaine, E.1    Sutherland, L.R.2    Macdonald, J.K.3
  • 2
    • 0032723990 scopus 로고    scopus 로고
    • Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine
    • D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999;50:667-71.
    • (1999) Gastrointest Endosc , vol.50 , pp. 667-671
    • D'haens, G.1    Geboes, K.2    Rutgeerts, P.3
  • 3
    • 66149148366 scopus 로고    scopus 로고
    • Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease
    • Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15:375-82.
    • (2009) Inflamm Bowel Dis , vol.15 , pp. 375-382
    • Mantzaris, G.J.1    Christidou, A.2    Sfakianakis, M.3
  • 4
    • 58149136086 scopus 로고    scopus 로고
    • Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: A high risk of relapse
    • Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-5.
    • (2009) Clin Gastroenterol Hepatol , vol.7 , pp. 80-85
    • Treton, X.1    Bouhnik, Y.2    Mary, J.Y.3
  • 5
    • 29244457275 scopus 로고    scopus 로고
    • Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
    • Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.
    • (2006) Gut , vol.55 , pp. 47-53
    • Ardizzone, S.1    Maconi, G.2    Russo, A.3
  • 6
    • 84873020600 scopus 로고    scopus 로고
    • Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
    • Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478.
    • (2012) Cochrane Database Syst Rev , vol.9 , pp. CD000478
    • Timmer, A.1    McDonald, J.W.2    Tsoulis, D.J.3
  • 7
    • 72049097420 scopus 로고    scopus 로고
    • Maintenance treatment with azathioprine in ulcerative colitis: Outcome and predictive factors after drug withdrawal
    • Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009;104:2760-7.
    • (2009) Am J Gastroenterol , vol.104 , pp. 2760-2767
    • Cassinotti, A.1    Actis, G.C.2    Duca, P.3
  • 8
    • 77955096659 scopus 로고    scopus 로고
    • Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): A study of changes in medical treatment and surgical resection rates
    • Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-6.
    • (2010) Gut , vol.59 , pp. 1200-1206
    • Ramadas, A.V.1    Gunesh, S.2    Thomas, G.A.3
  • 9
    • 53049110159 scopus 로고    scopus 로고
    • Natural history of pediatric Crohn's disease: A population-based cohort study
    • Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13.
    • (2008) Gastroenterology , vol.135 , pp. 1106-1113
    • Vernier-Massouille, G.1    Balde, M.2    Salleron, J.3
  • 10
    • 84907719849 scopus 로고    scopus 로고
    • Changes in medical treatment and surgery rates in inflammatory bowel disease: A nationwide cohort study 1979-2011
    • Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014;63: 1607-16.
    • (2014) Gut , vol.63 , pp. 1607-1616
    • Rungoe, C.1    Langholz, E.2    Andersson, M.3
  • 11
    • 84884369477 scopus 로고    scopus 로고
    • Early administration of azathioprine vs conventional management of Crohn's Disease: A randomized controlled trial
    • Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013;145:758-65.
    • (2013) Gastroenterology , vol.145 , pp. 758-765
    • Cosnes, J.1    Bourrier, A.2    Laharie, D.3
  • 12
    • 84884411282 scopus 로고    scopus 로고
    • Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease
    • Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145:766-74.
    • (2013) Gastroenterology , vol.145 , pp. 766-774
    • Panés, J.1    López-Sanromán, A.2    Bermejo, F.3
  • 13
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab azathioprine or combination therapy for Crohn's disease
    • Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3
  • 14
    • 84892737455 scopus 로고    scopus 로고
    • Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis
    • Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.pii: S0016-5085(13)01526-6.
    • (2014) Gastroenterology , vol.146 , pp. 392-400
    • Panaccione, R.1    Ghosh, S.2    Middleton, S.3
  • 15
    • 84891935282 scopus 로고    scopus 로고
    • The role of thiopurines in reducing the need for surgical resection in Crohn's disease
    • Chatu S, Subramanian V, Saxena S, et al. The role of thiopurines in reducing the need for surgical resection in Crohn's disease. Am J Gastroenterol 2014;109:23-34.
    • (2014) Am J Gastroenterol , vol.109 , pp. 23-34
    • Chatu, S.1    Subramanian, V.2    Saxena, S.3
  • 16
    • 62049083383 scopus 로고    scopus 로고
    • Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
    • Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
    • (2009) Am J Gastroenterol , vol.104 , pp. 760-767
    • Gisbert, J.P.1    Panés, J.2
  • 17
    • 77956997278 scopus 로고    scopus 로고
    • Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
    • Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8.
    • (2010) Gut , vol.59 , pp. 1363-1368
    • Sokol, H.1    Seksik, P.2    Carrat, F.3
  • 19
    • 75149161836 scopus 로고    scopus 로고
    • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
    • Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn Colitis 2010;4:28-62.
    • (2010) J Crohn Colitis , vol.4 , pp. 28-62
    • Dignass, A.1    Van Assche, G.2    Lindsay, J.O.3
  • 20
    • 0031889642 scopus 로고    scopus 로고
    • Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC
    • Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44:551-5.
    • (1998) Clin Chem , vol.44 , pp. 551-555
    • Dervieux, T.1    Boulieu, R.2
  • 21
    • 84898726547 scopus 로고    scopus 로고
    • Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: A meta-analysis
    • Moreau AC, Paul S, Del Tedesco E, et al. Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory Disease: a Meta-analysis. Inflamm Bowel Dis 2014;20:464-71.
    • (2014) Inflamm Bowel Dis , vol.20 , pp. 464-471
    • Moreau, A.C.1    Paul, S.2    Del Tedesco, E.3
  • 22
    • 84872308874 scopus 로고    scopus 로고
    • The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic
    • Smith M, Blaker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013;67:161-9.
    • (2013) Int J Clin Pract , vol.67 , pp. 161-169
    • Smith, M.1    Blaker, P.2    Patel, C.3
  • 23
    • 3242732900 scopus 로고    scopus 로고
    • Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease
    • Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-8.
    • (2004) Gut , vol.53 , pp. 1123-1128
    • Wright, S.1    Sanders, D.S.2    Lobo, A.J.3
  • 24
    • 8844267645 scopus 로고    scopus 로고
    • Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease
    • Hindorf U, Lyrenas E, Nilsson A, et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1105-12.
    • (2004) Scand J Gastroenterol , vol.39 , pp. 1105-1112
    • Hindorf, U.1    Lyrenas, E.2    Nilsson, A.3
  • 25
    • 0035186469 scopus 로고    scopus 로고
    • 6-mercaptopurine metabolite levels in children with inflammatory bowel disease
    • Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:450-4.
    • (2001) J Pediatr Gastroenterol Nutr , vol.33 , pp. 450-454
    • Gupta, P.1    Gokhale, R.2    Kirschner, B.S.3
  • 26
    • 79955828365 scopus 로고    scopus 로고
    • Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease
    • Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1301-7.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 1301-1307
    • Haines, M.L.1    Ajlouni, Y.2    Irving, P.M.3
  • 27
    • 34347393465 scopus 로고    scopus 로고
    • 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: Results from a randomized, controlled, open trial
    • Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53:1306-14.
    • (2007) Clin Chem , vol.53 , pp. 1306-1314
    • Reinshagen, M.1    Schutz, E.2    Armstrong, V.W.3
  • 28
    • 84890562279 scopus 로고    scopus 로고
    • Randomised clinical trial: Individualised vs. Weight-based dosing of azathioprine in Crohn's disease
    • Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther 2014;39: 163-75.
    • (2014) Aliment Pharmacol Ther , vol.39 , pp. 163-175
    • Dassopoulos, T.1    Dubinsky, M.C.2    Bentsen, J.L.3
  • 30
    • 84865713570 scopus 로고    scopus 로고
    • Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol
    • Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohn Colitis 2012;6:905-12.
    • (2012) J Crohn Colitis , vol.6 , pp. 905-912
    • Smith, M.A.1    Blaker, P.2    Marinaki, A.M.3
  • 31
    • 33846820178 scopus 로고    scopus 로고
    • Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
    • Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5:209-14.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 209-214
    • Sparrow, M.P.1    Hande, S.A.2    Friedman, S.3
  • 32
    • 84876380533 scopus 로고    scopus 로고
    • Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease
    • Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:363-9.
    • (2013) Inflamm Bowel Dis , vol.19 , pp. 363-369
    • Hoentjen, F.1    Seinen, M.L.2    Hanauer, S.B.3
  • 33
    • 76449085161 scopus 로고    scopus 로고
    • Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease
    • Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:640-7.
    • (2010) Aliment Pharmacol Ther , vol.31 , pp. 640-647
    • Ansari, A.1    Patel, N.2    Sanderson, J.3
  • 34
    • 27644565720 scopus 로고    scopus 로고
    • Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: Early experience of use in clinical practice
    • Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005;35:580-5.
    • (2005) Intern Med J , vol.35 , pp. 580-585
    • Gearry, R.B.1    Barclay, M.L.2    Roberts, R.L.3
  • 35
    • 0027164795 scopus 로고
    • Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience
    • Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
    • (1993) Gut , vol.34 , pp. 1081-1085
    • Connell, W.R.1    Kamm, M.A.2    Ritchie, J.K.3
  • 36
    • 0018117298 scopus 로고
    • Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
    • O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;2:955-7.
    • (1978) Lancet , vol.2 , pp. 955-957
    • O'donoghue, D.P.1    Dawson, A.M.2    Powell-Tuck, J.3
  • 37
    • 84875890217 scopus 로고    scopus 로고
    • Myelosuppression monitoring after immunomodulator initiation in veretans with inflammatory bowel disease: A national practice audit
    • Hou JK, Kramer JR, Richardson P, et al. Myelosuppression monitoring after immunomodulator initiation in veretans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther 2012;36:1049-56.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 1049-1056
    • Hou, J.K.1    Kramer, J.R.2    Richardson, P.3
  • 38
    • 34250797604 scopus 로고    scopus 로고
    • Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review
    • Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-27.
    • (2007) Am J Gastroenterol , vol.102 , pp. 1518-1527
    • Gisbert, J.P.1    Gonzalez-Lama, Y.2    Mate, J.3
  • 39
    • 77957192395 scopus 로고    scopus 로고
    • Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine
    • Seksik P, Mary JY, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis 2011;17:565-72.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 565-572
    • Seksik, P.1    Mary, J.Y.2    Beaugerie, L.3
  • 40
    • 41349088375 scopus 로고    scopus 로고
    • Risk factors for opportunistic infections in patients with inflammatory bowel disease
    • Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36.
    • (2008) Gastroenterology , vol.134 , pp. 929-936
    • Toruner, M.1    Loftus, E.V.2    Harmsen, W.S.3
  • 41
    • 11144316621 scopus 로고    scopus 로고
    • Disseminated primary varicella after initiation of infliximab for Crohn's disease
    • Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004;99:2503-4.
    • (2004) Am J Gastroenterol , vol.99 , pp. 2503-2504
    • Leung, V.S.1    Nguyen, M.T.2    Bush, T.M.3
  • 42
    • 80054753242 scopus 로고    scopus 로고
    • Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis
    • Biank VF, Sheth MK, Talano J, et al. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011;159: 808-12.
    • (2011) J Pediatr , vol.159 , pp. 808-812
    • Biank, V.F.1    Sheth, M.K.2    Talano, J.3
  • 43
    • 67349134712 scopus 로고    scopus 로고
    • European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in IBD
    • Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in IBD. J Crohn Colitis 2009;3:47-91.
    • (2009) J Crohn Colitis , vol.3 , pp. 47-91
    • Rahier, J.F.1    Ben-Horin, S.2    Chowers, Y.3
  • 44
    • 70349314937 scopus 로고    scopus 로고
    • Inflammatory bowel disease and lymphoproliferative disorders: The dust is starting to settle
    • Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:1427-36.
    • (2009) Gut , vol.58 , pp. 1427-1436
    • Sokol, H.1    Beaugerie, L.2
  • 45
    • 70449100743 scopus 로고    scopus 로고
    • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study
    • Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
    • (2009) Lancet , vol.374 , pp. 1617-1625
    • Beaugerie, L.1    Brousse, N.2    Bouvier, A.M.3
  • 46
    • 84857801058 scopus 로고    scopus 로고
    • Inflammatory bowel disease therapies and cancer risk: Where are we and where are we going?
    • Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 2012;61:476-83.
    • (2012) Gut , vol.61 , pp. 476-483
    • Beaugerie, L.1
  • 47
    • 0018599063 scopus 로고
    • Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
    • Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6.
    • (1979) Br Med J , vol.2 , pp. 1461-1466
    • Kinlen, L.J.1    Sheil, A.G.2    Peto, J.3
  • 48
    • 84878557076 scopus 로고    scopus 로고
    • Use of azathioprine and the risk of cancer in inflammatory bowel disease
    • Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013;177:1296-305.
    • (2013) Am J Epidemiol , vol.177 , pp. 1296-1305
    • Pasternak, B.1    Svanstrom, H.2    Schmiegelow, K.3
  • 49
    • 84905581315 scopus 로고    scopus 로고
    • Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
    • Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-23.
    • (2014) Gut , vol.63 , pp. 1416-1423
    • Beaugerie, L.1    Carrat, F.2    Colombel, J.F.3
  • 50
    • 84864225717 scopus 로고    scopus 로고
    • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease
    • Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-9.
    • (2012) Gastroenterology , vol.143 , pp. 390-399
    • Long, M.D.1    Martin, C.F.2    Pipkin, C.A.3
  • 51
    • 80054862378 scopus 로고    scopus 로고
    • Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
    • Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141: 1621-8.
    • (2011) Gastroenterology , vol.141 , pp. 1621-1628
    • Peyrin-Biroulet, L.1    Khosrotehrani, K.2    Carrat, F.3
  • 52
    • 80054865266 scopus 로고    scopus 로고
    • Increased risk of non-melanoma skin cancers among individuals with inflammatory bowel disease
    • Singh H, Nugent Z, Demers AA, et al. Increased risk of non-melanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612-20.
    • (2011) Gastroenterology , vol.141 , pp. 1612-1620
    • Singh, H.1    Nugent, Z.2    Demers, A.A.3
  • 53
    • 84892453349 scopus 로고    scopus 로고
    • Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis
    • Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:210-18.
    • (2014) Clin Gastroenterol Hepatol , vol.12 , pp. 210-218
    • Singh, S.1    Nagpal, S.J.2    Murad, M.H.3
  • 54
    • 49749129257 scopus 로고    scopus 로고
    • Abnormal Pap smears in inflammatory bowel disease
    • Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1158-60.
    • (2008) Inflamm Bowel Dis , vol.14 , pp. 1158-1160
    • Kane, S.1
  • 55
    • 84904391778 scopus 로고    scopus 로고
    • Increased risk of acute myeloid leukemias and myelodysplastic syndromes in pateints with past exposure to thiopurines for Inflammatory Bowel Disase
    • Published Online First: 26 Feb 2014
    • Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in pateints with past exposure to thiopurines for Inflammatory Bowel Disase. Clin Gastroenterol hepatol 2014:pii: S1542-3565(14)00311-5. Published Online First: 26 Feb 2014. doi:10.1016/j.cgh.2014.02.026
    • (2014) Clin Gastroenterol Hepatol
    • Lopez, A.1    Mounier, M.2    Bouvier, A.M.3
  • 56
    • 78650239266 scopus 로고    scopus 로고
    • A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease
    • Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 36-41
    • Kotlyar, D.S.1    Osterman, M.T.2    Diamond, R.H.3
  • 57
    • 84886267819 scopus 로고    scopus 로고
    • Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: A nationwide retrospective cohort study
    • Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013;145:1007-15.
    • (2013) Gastroenterology , vol.145 , pp. 1007-1015
    • Khan, N.1    Abbas, A.M.2    Lichtenstein, G.R.3
  • 58
    • 22644446331 scopus 로고    scopus 로고
    • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    • Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
    • (2005) Gut , vol.54 , pp. 1121-1125
    • Kandiel, A.1    Fraser, A.G.2    Korelitz, B.I.3
  • 59
    • 36549059250 scopus 로고    scopus 로고
    • Mortality by medication use among patients with inflammatory bowel disease, 1996-2003
    • Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007;133:1779-86.
    • (2007) Gastroenterology , vol.133 , pp. 1779-1786
    • Hutfless, S.M.1    Weng, X.2    Liu, L.3
  • 60
    • 44949242296 scopus 로고    scopus 로고
    • Immunosuppressant medications and mortality in inflammatory bowel disease
    • Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-35.
    • (2008) Am J Gastroenterol , vol.103 , pp. 1428-1435
    • Lewis, J.D.1    Gelfand, J.M.2    Troxel, A.B.3
  • 61
    • 84870915040 scopus 로고    scopus 로고
    • Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010
    • Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013;11:43-8.
    • (2013) Clin Gastroenterol Hepatol , vol.11 , pp. 43-48
    • Jess, T.1    Frisch, M.2    Simonsen, J.3
  • 62
    • 0034075584 scopus 로고    scopus 로고
    • Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
    • Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
    • (2000) Gastroenterology , vol.118 , pp. 1018-1024
    • Lewis, J.D.1    Schwartz, J.S.2    Lichtenstein, G.R.3
  • 63
    • 84893714895 scopus 로고    scopus 로고
    • Natural history of elderly-onset inflammatory bowel disease: A population-based cohort study
    • Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014;63:423-32.
    • (2014) Gut , vol.63 , pp. 423-432
    • Charpentier, C.1    Salleron, J.2    Savoye, G.3
  • 64
    • 33646147141 scopus 로고    scopus 로고
    • Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 621-630
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 65
    • 78649661962 scopus 로고    scopus 로고
    • Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease
    • Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 30-35
    • Cottone, M.1    Kohn, A.2    Daperno, M.3
  • 66
    • 34548490280 scopus 로고    scopus 로고
    • Crohn's disease patients' risk-benefit preferences: Serious adverse event risks versus treatment efficacy
    • Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769-79.
    • (2007) Gastroenterology , vol.133 , pp. 769-779
    • Johnson, F.R.1    Ozdemir, S.2    Mansfield, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.